All In Biotech

Drug Trial Radar · NCT04907370

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Toripalimab Combined With Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multi-center, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

532

Actual

Start

Aug 1, 2021

Primary completion

Mar 1, 2025

Study completion Mar 1, 2027

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Junshi Bioscience Co., Ltd.
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab incorporated into induction chemotherapy and radiotherapy) in high-risk locoregionally advanced nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

  • PD-1 blocking antibodyDrug

    1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC. 2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT. 3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1

  • GemcitabineDrug

    Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles

  • Cisplatin (80mg/m2)Drug

    Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles

  • Cisplatin (100mg/m2)Drug

    Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

  • Intensity-modulated radiotherapyRadiation

    Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Failure-free survival (FFS)Time frame: 3-year
  2. Incidence rate of all-grade vomitingTime frame: Through study completion, an average of 1 year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • First People's Hospital of Foshan

    Foshan, Guangdong, China

  • Panyu central hospital

    Guangzhou, Guangdong, China

  • Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Hubei Province Cancer Hosiptal

    Wuhan, Hubei, China

  • Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • Jiangxi Province Cancer Hospital

    Nanchang, Jiangxi, China

  • Zhejiang Province Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.